Business Standard
Saturday, Sep 04, 2010
drived banner
drived banner
  Advanced Search
Feedback | RSS
Content Guide
Follow us on  
||Companies & Industry||||||| 
 Section Home | News Now | Today's Paper | Q&A | People in the News | Industry News | Features | The Compass | Research & Analysis | Opinion | Corporate Results
Home > Companies & Industry Live Markets | Smart Portfolios II | Commodities
  Search:
Pfizer to sell 3 plants
Rumi Dutta / Mumbai October 24, 2003
Company looking at brand acquisitions to strengthen product portfolio

 
Pfizer, the world’s largest drug maker, has embarked on a restructuring of its operations in India and will soon put three of its five manufacturing facilities on the block. It will also look at brand acquisitions to strengthen its product portfolio.
 
The move is part of the ongoing operational integration of Pfizer India with the recently acquired Pharmacia Corporation’s Indian arms, Pharmacia Healthcare and Pharmacia India, and Parke-Davis.
 
Pfizer has decided to put Pharmacia’s Ankeleshwar unit up for sale. At the same time, following the merger with Parke-Davis, Pfizer India is set to invite bids for the sale of the latter’s manufacturing facility in Hyderabad.
 
The drug major is also studying the feasibility of its Chandigarh plant, where operations could soon be discontinued, and the unit put up for sale.
 
Pfizer consequently will consolidate its manufacturing operations in its Thane facility near Mumbai. It has invested around Rs 13.6 crore to upgrade the facility.
 
Kewal Handa, executive director (finance), Pfizer, told Business Standard,: “We are rationalising our manufacturing operations in India. We are trying to design the right mix of third-party manufacturing, outsourcing and in-house production.
 
“We have discontinued operations at Pharmacia’s unit at Ankeleshwar. The board is yet to take a final call on the disposal of the unit. The products that were manufactured at this unit may be shifted to our Thane facility or may be given out for third-party manufacturing.” A voluntary retirement scheme has been offered to its employees.
 
The other manufacturing unit of Pharmacia in Bangalore, which manufactures intra-ocular lenses, will be retained.
 
Pfizer’s Chandigarh plant, a fermentation facility, produces oxytetracycline and its salts and salinomycin 350, catering to local demand, and chlopropamide, which is exported.
 
Parke Davis' plant has been closed for some time now and golden handshakes given to around 500 employees.
 
Pharmacia Corporation was globally acquired by Pfizer Inc, while Parke Davis' parent Warner Lambert was merged with Pfizer in 2000.
 
Pharmacia Corporation held a 75 per cent stake in its Indian arm, Pharmacia Healthcare (formerly Abbott) and Pharmacia India was a 100 per cent subsidiary of the US parent. 
 
On a recast mode
  • Pharmacia’s Ankeleshwar unit will be put up for sale
  • Pfizer India will invite bids for the sale of its manufacturing facility in Hyderabad
  • Pfizer’s Chandigarh plant could also be shut
  • The company will consolidate its manufacturing operations in its Thane facility near Mumbai
 
Arrow Other Stories     
- Markets have a muted closing
- FII-TO-FII TRADES: PNB traded at 10% premium
- Infosys open to foreigner as Chairman: Murthy
- US economy on right path, but not fast enough: Obama
- The Loot to file DRHP with Sebi by December
More  
  Read Business news in 
   Banking Solutions that are a perfect fit. Know more
   Your 1st Step in Share markets with Sharekhan!
   Click here to visit Business Standard SME Buzz
   Required telecallers in Mumbai full time or part time...
   5lacs to invest? Contact Sharekhan's PMS Advisor
  GiftwithLove.com: Same Day Delivery of Flowers/ Cake/Gift in India
Markets Update Powered by   
   Smart Moves More 
 CompanyLast (Rs)  Remarks
 Venkys (India) Ltd860.40   Moves up on expansion plans
 Petronet LNG Ltd113.85   Gains on expansion plans
 BEML Ltd1,134.30   Gains on signing MoU with Cades Digitech
 Trent Ltd1,131.05   Reliance Cap buys 8.68% stake; stk soars
   Top Gainers
Company Last (Rs) Gain (%)
Hero Honda Motor 1,736.15 2.14 
Reliance Infra. 1,030.45 1.60 
Bharti Airtel 339.40 1.60 
 
   Top Losers
Company Last (Rs) Gain (%)
Jindal Steel 683.25 -2.10 
JP Associates 112.95 -1.53 
Hindalco Inds. 170.40 -1.47 
   Expert Speaks
Ujjval
'The overall sentiment is cautious'
Jyoti Prasad, Head (Investment Banking), Asit. C Mehta
   Live Commentary
- The Sensex finally ended at 18,221 down 16 points and Nifty closed at 5479 down 6 points
- Sensex losers : Jindal Steel, Jaiprakash Associates and Hindalco Industries
   Discussion Board / User Comments    
Display Name  Email-Id  
Post your comment
Most Popular
Read
E-Mailed
Commented
   
- Cancer drugs may become cheaper after govt study
- N-subs: India debates, China struggles
- Pak envoy sees Pawar's hand in ICC suspension
- Govt clears $5-billion airplane purchases
- Cong election for president over, Jagan likely to face the heat
 
 More  
BS Poll
Cast Your Vote
 
   
 
Will demand for home loans fall with the withdrawal of tax benefits on principal repayment?
  Yes  No
Submit

  Hot Searches  
 
Navi Mumbai airport |  CAT 2010 |  sks microfinance |  Orkut |  Nuclear Liability Bill |  noel tata |  US economy |  income tax refund |  Mahindra Satyam |  Kashmir |  Union Carbide |  Cairn India |  iPhone |  Rupee Symbol |  IFCI bonds |  Reliance Industries |  3G  |  SEBI |  ULIP |  iPad |  IPL |  BSNL |  Coal India IPO |  BSE |  NSE |  Amitabh Bachchan |  Mukesh Ambani |  Anil Ambani |  Bollywood |  TCS |  Infosys |  Pranab Mukherjee |  Maruti Suzuki |  Sonia Gandhi |  Rahul Gandhi |  New Pension Scheme |  Service tax |  Reliance |  RBI |  GDP |  Gold |  Ratan Tata |  ICICI |  B-School |  Sensex |  Tax calculator |  Home Loan |  Personal Finance |  inflation |  oil prices |  Barack Obama |   
 
  Member Area Write to the Editor RSS Archives Advanced Search
  Subscribe to BS print product BS e-paper Newsletter Portfolio Tracker
  BS Products BS Hindi BS Motoring
FOR HOT PRODUCTS
BS Bazaar.com
Home | Markets & Investing | Companies & Industry | Banking & Finance | Economy & Policy | Opinion
Life & Leisure | Management & Marketing | Tech World
About Us | Partner With Us | Code of Conduct | Careers | Advertise with us| Terms & Conditions | Disclaimer | Site Map | Contact Us | Feedback